MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna, Austria LSX Investival Showcase Europe 2025, November 17Location: Old Billingsgate, London, United Kingdom Jefferies Global Healthcare Conferenc ...

To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise in CNS and immuno-oncology MADRID and CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, is pleased to announce the strategic collaboration with Dr. Iman Barilero, PharmD, PhD, as Senior Advisor for Regulatory Affairs to suppo ...

Core Insights - Oryzon Genomics has received a Decision to Grant from the European Patent Office for its patent application EP20712594.9, which covers the use of iadademstat in combination with PD1 or PD-L1 inhibitors for cancer therapy, including small cell lung cancer (SCLC) [1][2] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, particularly in CNS disorders and oncology [5] - The company has a clinical portfolio that includes two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [5] - Oryzon's team consists of experienced professionals from the pharmaceutical industry, with locations in Barcelona, Boston, and San Diego [5] Product Development - Iadademstat is a selective inhibitor of the epigenetic enzyme LSD1, currently being investigated in various clinical trials for hematologic cancers and solid tumors [6] - The drug is being tested in combination with PD-L1 inhibitors in a Phase I/II trial for extensive-disease SCLC patients, sponsored by the U.S. National Cancer Institute [4][6] - Iadademstat has shown promising safety and efficacy in trials for acute myeloid leukemia (AML) and is being evaluated for other indications, including sickle cell disease and essential thrombocythemia [6] Patent and Market Position - The granted patent for iadademstat will remain in force until at least 2040, with corresponding patents already allowed in Australia and Russia, and applications pending in the U.S., Japan, and China [2][3] - The patent strengthens Oryzon's position in the market for cancer therapies that utilize immune checkpoint inhibitors [3]

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a European leader in epigenetics, focusing on personalized medicine for CNS disorders and oncology [3] Company Events - Oryzon management will participate in several upcoming events, including the Drug Discovery Innovation Programme on September 25-26 in Barcelona, and the Paris Midcap Event from September 30 to October 1 [1][2] - Additional events include the BME Investor Access Event on October 7 in Paris, BIOSPAIN 2025 from October 7-9 in Barcelona, and the 25th Sachs Annual Biotech in Europe Forum on October 8-9 in Basel, where Oryzon will present on October 8 at 13:45 CET [2] Company Overview - Founded in 2000 in Barcelona, Oryzon has a strong clinical portfolio featuring two LSD1 inhibitors: vafidemstat, which is Phase III-ready for CNS, and iadademstat, currently in Phase II for oncology [3] - The company is also developing ORY-4001, a clinical candidate targeting HDAC-6 for potential applications in CMT and ALS, alongside a robust platform for biomarker identification and target validation for various diseases [3]

Core Insights - Oryzon Genomics is expanding its patent portfolio for its clinical-stage LSD1 inhibitors, iadademstat and vafidemstat, with recent patent grants from the Australian and European patent offices [1][4]. Patent Developments - The Australian Patent Office granted a patent for iadademstat, covering its use in combination with PD1 or PD-L1 inhibitors for cancer treatment, including small cell lung cancer (SCLC), valid until at least 2040 [2]. - A corresponding patent for iadademstat has also been granted in Russia, with pending applications in Europe, the U.S., Japan, China, and other countries [2]. - The European Patent Office granted a patent for vafidemstat, which covers its use in treating aggressiveness and social withdrawal associated with CNS diseases, valid until at least 2038 [4]. - Additional patents for vafidemstat have been granted in various countries, with pending applications in others [4]. Clinical Trials and Research - Iadademstat is being evaluated in a Phase I/II trial in combination with PD-L1 inhibitors for extensive disease SCLC, sponsored by the U.S. National Cancer Institute [3]. - Vafidemstat is in advanced clinical development for treating aggression in psychiatric disorders, with a Phase III trial for Borderline Personality Disorder (BPD) and ongoing Phase II trials for Autism Spectrum Disorder (ASD) and schizophrenia [5][10]. - Iadademstat has shown promising results in various trials, including a Phase IIa trial in combination with azacitidine for acute myeloid leukemia (AML) [9]. Company Overview - Oryzon Genomics, founded in 2000, is a clinical-stage biopharmaceutical company based in Barcelona, Spain, focusing on epigenetics and personalized medicine in CNS disorders and oncology [7]. - The company has a robust clinical portfolio, including two LSD1 inhibitors, with ongoing research into other epigenetic targets [7].

Core Points - Oryzon Genomics has been selected as a Finalist in the 2025 European Lifestars Awards for the category Post-IPO Raise of the Year in the European Mediterranean region [1][2] - The nomination is attributed to the successful completion of a €30 million capital increase, which involved issuing 12.76 million new shares at €2.35 per share, reflecting a 15.44% discount to the 5-day volume-weighted average price and a 19.38% discount to the April 22, 2025 closing price [3] - The capital raise was significantly oversubscribed, with a U.S.-based institutional investor contributing €15 million, and additional participation from investors across the U.S., Europe, and Spain [3] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, particularly in CNS disorders and oncology [5] - The company has an advanced clinical portfolio that includes two LSD1 inhibitors, vafidemstat (Phase III-ready) and iadademstat (Phase II), along with other pipeline assets targeting various epigenetic mechanisms [5] - Oryzon has established a strong platform for biomarker identification and target validation for a range of malignant and neurological diseases [5]

Core Insights - Oryzon Genomics has received EMA approval to initiate a Phase Ib clinical trial of iadademstat for sickle cell disease (SCD), marking the first investigation of this drug in a non-malignant hematological indication [1][2] Company Overview - Oryzon Genomics is a clinical-stage biopharmaceutical company based in Barcelona, Spain, specializing in epigenetics and personalized medicine, particularly in CNS disorders and oncology [7] - The company has a robust clinical portfolio, including two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [7] Clinical Trial Details - The Phase Ib study, named RESTORE, will enroll 40 adult patients with SCD across multiple sites in Spain, focusing on safety, tolerability, and establishing the Recommended Phase 2 dose (RP2D) [2] - Secondary objectives of the trial include assessing the drug's ability to induce fetal hemoglobin (HbF) levels [2] Sickle Cell Disease Context - SCD is a chronic inherited blood disorder affecting approximately 7.7 million people globally, characterized by the production of hemoglobin S (HbS) leading to various complications [3][5] - The disease results in significant health issues, including vaso-occlusive crises, hemolytic anemia, and reduced quality of life, highlighting a substantial unmet medical need for effective treatments [4] Market Potential - The SCD treatment market is projected to grow from approximately USD 3 billion in 2025 to around USD 8 billion by 2032, indicating strong commercial potential for effective therapies [5] - Existing gene therapies face challenges due to technical complexity and high costs, limiting patient access [5] Iadademstat's Mechanism and Other Investigations - Iadademstat is a selective LSD1 inhibitor showing promise in increasing HbF levels, which may mitigate the disease's pathological effects [5][8] - The drug is also under investigation in various oncology trials, including combinations with gilteritinib and azacitidine for acute myeloid leukemia (AML) [6][8]

MADRID and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the half-year ended June 30, 2025 and provided a corporate update on recent developments. Since last December, the company has secured $61 million in funding, including $35.2 million (€30 million) from a successful capital raise completed in April through a straight equity iss ...

Core Insights - Oryzon Genomics is participating in the 2025 Phelan-McDermid Syndrome Congress, highlighting its commitment to addressing rare genetic disorders through its research and development efforts [1][2] Company Participation and Events - Oryzon is sponsoring the CureSHANK's 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium and the III Scientific Conference of the Spanish Phelan-McDermid Syndrome Association, which will take place from June 26 to June 29, 2025 [2] - Dr. Jordi Xaus, Oryzon's Chief Scientific Officer, will engage in a panel discussion on industry perspectives related to clinical trials and business considerations [1][7] Research and Development Focus - Oryzon is exploring the potential of vafidemstat, an LSD1 inhibitor, for treating rare monogenic psychiatric disorders, including Phelan-McDermid Syndrome (PMS) and Autism Spectrum Disorder (ASD) [3][5] - In the Phase IIb PORTICO trial for Borderline Personality Disorder (BPD), vafidemstat showed nominal statistical significance in reducing agitation and aggression, which are also key symptoms in PMS [3][7] Collaborations and Publications - Oryzon has collaborated with the Medical and Molecular Genetics Institute and the Research Institute La Paz Hospital to publish findings on the clinical characterization of PMS, which will support future clinical trials with vafidemstat [4] - The company has received €13.5 million from the EU IPCEI Med4Cure project to validate epigenetic drugs like vafidemstat through a personalized medicine approach for rare diseases [5] Product Pipeline and Clinical Trials - Vafidemstat is currently the only LSD1 inhibitor in clinical development for central nervous system (CNS) disorders, with ongoing trials in various psychiatric conditions, including BPD and schizophrenia [6][8] - The drug has demonstrated efficacy in reducing cognitive impairment and neuroinflammation in preclinical models, and it is advancing towards Phase III trials following positive results from earlier studies [8]

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is focused on epigenetics and personalized medicine, particularly in CNS disorders and oncology [3][4][5] Company Overview - Founded in 2000 in Barcelona, Spain, Oryzon is recognized as a European leader in epigenetics with a strong clinical portfolio [3] - The company has two LSD1 inhibitors: vafidemstat (Phase III-ready for CNS) and iadademstat (Phase II for oncology) [3] - Oryzon is also developing ORY-4001, targeting HDAC-6 for conditions like CMT and ALS, and has a robust platform for biomarker identification [3] Clinical Development - Iadademstat (ORY-1001) is a selective LSD1 inhibitor showing promising results in hematologic cancers, with ongoing trials in combination therapies for AML [4] - Vafidemstat (ORY-2001) is a CNS-optimized LSD1 inhibitor demonstrating efficacy in cognitive impairment and neuroinflammation, with positive results in various Phase IIa trials [5][6] Upcoming Events - Oryzon will participate in several international events, including Foro Medcap 2025 in Madrid, BIO International Convention 2025 in Boston, and Discovery and Development Europe 2025 in Basel, where they will engage with investors and present their research [2]